Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review)

1. Carter F, Alsayb M, Marshall JK, Yuan Y (2017) Mesalamine (5-ASA) for the prevention of recurrent diverticulitis. Cochrane Database Syst Rev 10:CD009839

   PubMed  Google Scholar 

2. Stollman N, Smalley W, Hirano I, Institute Clinical Guidelines Committee AGA (2015) American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. Gastroenterology 149(7):1944–1949

   Article  PubMed  Google Scholar 

3. Cuomo R, Barbara G, Pace F, Annese V, Bassotti G, Binda GA, Casetti T, Colecchia A, Festi D, Fiocca R, Laghi A, Maconi G, Nascimbeni R, Scarpignato C, Villanacci V, Annibale B (2014) Italian consensus conference for colonic diverticulosis and diverticular disease. United Eur Gastroenterol J 2(5):413–442

   Article  Google Scholar 

4. Kruis W, Germer CT, Leifeld L, German Society for Gastroenterology, Digestive and Metabolic Diseases and The German Society for General and Visceral Surgery (2014) Diverticular disease: guidelines of the german society for gastroenterology, digestive and metabolic diseases and the german society for general and visceral surgery. Digestion 90(3):190–207

   Article  PubMed  Google Scholar 

5. Dirks K, Calabrese E, Dietrich CF, Gilja OH, Hausken T, Higginson A, Hollerweger A, Maconi G, Maaser C, Nuernberg D, Nylund K, Pallotta N, Ripolles T, Romanini L, Saftoiu A, Serra C, Wüstner M, Sporea I (2019) EFSUMB Position Paper: recommendations for Gastrointestinal Ultrasound (GIUS) in Acute Appendicitis and Diverticulitis. Ultraschall Med 40(2):163–175

   Article  PubMed  Google Scholar 

6. Kruis W, Kardalinos V, Eisenbach T, Lukas M, Vich T, Bunganic I, PokrotnieksJ Derova J, Kondrackiene J, Safadi R, Tuculanu D, Tulassay Z, Banai J, Curtin A, Dorofeyev AE, Zakko SF, Ferreira N, Björck S, Diez Alonso MM, Mäkelä J, Talley NJ, Dilger K, Greinwald R, Mohrbacher R, Spiller R (2017) Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Aliment Pharmacol Ther 46(3):282–291

   Article  CAS  PubMed  PubMed Central  Google Scholar 

7. Khan RMA, Ali B, Hajibandeh S, Hajibandeh S (2018) Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials. Colorectal Dis 20(6):469–478

   Article  CAS  PubMed  Google Scholar 

8. Severi C, Carabotti M, Cicenia A, Pallotta L, Annibale B (2018) Recent advances in understanding and managing diverticulitis. F1000Res. https://doi.org/10.12688/f1000research.14299.1

   Article  PubMed  PubMed Central  Google Scholar 

9. Barbara G, Scaioli E, Barbaro MR, Biagi E, Laghi L, Cremon C, Marasco G, Colecchia A, Picone G, Salfi N, Capozzi F, Brigidi P, Festi D (2017) Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut 66(7):1252–1261

   Article  CAS  PubMed  Google Scholar 

10. Cohen E, Fuller G, Bolus R, Modi R, Vu M, Shahedi K, Shah R, Atia M, Kurzbard N, Sheen V, Agarwal N, Kaneshiro M, Yen L, Hodgkins P, Erder MH, Spiegel B (2013) Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol 11(12):1614–1619

    Article  PubMed  PubMed Central  Google Scholar 

11. Kruis W, Meier E, Schumacher M, Mickisch O, Greinwald R, Mueller R, German SAG-20 Study Group (2013) Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon- a placebo-controlled study. Aliment Pharmacol Ther 37(7):680–690

    Article  CAS  PubMed  Google Scholar 

12. Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G, Rodino S, D’Amico T, Sacca N, Portincasa P, Capezzuto E, Lattanzio R, Spadaccini A, Fiorella S, Polimeni F, Polimeni N, Stoppino V, Stoppino G, Giorgetti GM, Aiello F, Danese S (2013) Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease—a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 38(7):741–751

    Article  CAS  PubMed  Google Scholar 

13. Cremon C, Carabotti M, Cuomo R, Pace F, Andreozzi P, Barbaro MR, Annibale B, Barbara G, on behalf of the REMAD Group (2019) Italian nationwide survey of pharmacologic treatments in diverticular disease: results from the REMAD registry. United Eur Gastroenterol J 7(6):815–824. https://doi.org/10.1177/2050640619845990

    Article  Google Scholar 

Download references